|                         | Cover page                                  |  |  |  |  |  |
|-------------------------|---|--|--|--|--|--|
| Meeting                 | Public Board                                |  |  |  |  |  |
| Paper Title             | Performance Management Arrangements 2020/21 |  |  |  |  |  |
| Date of meeting         | 26 March 2020                               |  |  |  |  |  |
| Date paper was written  | 20 March 2020                               |  |  |  |  |  |
| Responsible<br>Director | Chief Executive                             |  |  |  |  |  |
| Author                  | Louise Barnett                              |  |  |  |  |  |

### **Executive Summary**

It is extremely important, particularly from a CQC well-led perspective, that we ensure that high quality reporting, risk management and escalation processes are in place to support the delivery of our operational plan.

This paper proposes a number of improvements to the Trust's performance management arrangements for 2020/21 to strengthen the current approach, addressing the feedback from the CQC and building on the work that has already commenced (e.g. review of the Integrated Performance Report – see January board paper).

It is recommended that the Trust Board **notes** the contents of this paper and support the proposed approach.

Previously considered by

N/A

| The Board (Committee)   | is asked to:   |  |  |
|---|--|--|--|
| ☐ Approve   | ☐ Receive  | ■ Note   | ☐ Take Assurance   |
| To formally receive and discuss a report and approve its recommendations or a particular course of action | To discuss, in depth, noting the implications for the Board or Trust without formally approving it | For the intelligence of the Board without in-depth discussion required | To assure the Board that effective systems of control are in place |

| Link to CQC de                                     | omain:                                   |  |                                  |                   |
|--|--|--|----------------------------------|-------------------|
| ☐ Safe   | ☐ Effective                              | ☐ Caring                                     | ☐ Responsive                     | <b>■</b> Well-led |
|  |  |  |                                  |                   |
|  | PATIENT AND FAN<br>to improve health     | _  | working with our patie           | nts and families  |
| Link to<br>strategic<br>objective(s)               | ☐ HEALTHIEST HALF<br>Choices' for all ou |  | ith our partners to pror         | note 'Healthy     |
| objective(s)                                       | ■ LEADERSHIP Inno                        | ative and Inspiration                        | Leadership to deliver            | our ambitions     |
|  | OUR PEOPLE Crea                          | ating a great place to                       | work                             |                   |
| Link to Board<br>Assurance<br>Framework<br>risk(s) | BAF risks 561 and                        | 670  |                                  |                   |
|  |  |  |                                  |                   |
| Equality<br>Impact                                 | ⊙ Stage 1 only (no n                     | egative impact ident                         | ified)                           |                   |
| Assessment   |  | nded (negative impac<br>hed for Board approv | ct identified and equali<br>val) | ty impact         |
| Freedom of Information                             | • This document is                       | for full publication                         |                                  |                   |
| Act (2000)   | C This document inc                      | cludes FOIA exempt i                         | nformation                       |                   |
| status   | C This whole docum                       | nent is exempt under                         | the FOIA                         |                   |
| Financial assessment                               | No financial impac                       | <u> </u>                                     |                                  |                   |

### **Main Paper**

#### Situation

The quality of the Trust's performance management mechanisms and reporting need to be strengthened to increase executive and board assurance around operational plan delivery, whilst also supporting more timely and proactive decision-making so that potential risks and issues can be mitigated before they crystallise (wherever possible).

### Background

The performance management arrangements currently in place need to be improved for 2020/21, particularly in relation to the quality of reporting, risk management and escalation processes that support the delivery of the Trust's operational plan. A number of focus areas have been identified:

- Improving up-front planning and prioritisation, increasing specificity around deliverables and setting more realistic short to medium term objectives
- Better alignment, clarity and transparency of key deliverables particularly when delegating to teams and business owners across the organisation
- Enhancing quality, timeliness and proactivity of performance reporting and strengthening performance management processes, including mitigation planning and appropriate escalation
- Higher quality decision-making and more dynamic prioritisation processes, particularly when new emergent priorities require urgent management attention
- Increasing communication and engagement activities to keep teams, individuals and other stakeholders engaged and fully informed of progress/changes

Whilst work has already commenced on the development of solutions in these areas, over the last month management attention has been focused on the finalisation of the operational plan and budget for 2020/21 (as well as dealing with current operational challenges).

This paper outlines a proposed approach to address the areas of focus identified above, building on the work that has already started e.g. planned improvements to the Trust's Integrated Performance Reporting / dashboards (paper provided to the Board in January 2020).

#### Assessment

It is proposed that the Trust's performance management arrangements are strengthened to incorporate the output of the following activities:

- Review and alignment of executive portfolios and priorities
- Review and alignment of roles and accountabilities of supporting teams and groups, including assessment of delivery capacity and capability (incorporating care groups and other committees/groups)
- Review and alignment of Standing Orders, Standing Financial Instructions and Scheme of Delegation (to ensure that appropriate individuals and groups are fully empowered to make decisions)
- Review and development of the risk management framework
- Development of detailed plans to support the delivery of transformational objectives and goals - confirming business owners, support requirements and milestones
- Further development and finalisation of Integrated Performance Reporting and required performance dashboards ('single version of the truth'). Development and

- implementation of a data quality 'kitemark' to provide increased assurance around the accuracy of performance information
- Development and roll out of a best practice performance and accountability framework (using the approach described in appendix 2). The framework will incorporate more rigorous performance management mechanisms, improvements to the flow of performance meetings and a focus on proactive risk analysis and decision-making
- Development and implementation of staff and stakeholder engagement activities to secure buy-in to both operational plan objectives and new performance management arrangements - timing and approach to be mindful of operational pressures (particularly COVID 19)

### Proposed key milestones and timelines:

- New IPR/performance dashboards for 2020/21 approved April
- New IPR/performance dashboards for 2020/21 implemented May (month 1 reporting) onwards
- Performance management framework approved April
- Operational Plan transformational objectives and goals finalised April
- Initial engagement sessions with teams and staff members May
- Roll out and embed new performance management arrangements June onwards

Over the next few months, performance management arrangements will continue to operate in their current form (with incremental improvements) whilst we fully develop, implement and embed the proposed new arrangements. February (month 11) performance reports are attached at appendix 1 for information.

### Recommendation

It is recommended that the Trust Board **notes** the contents of this paper and support the proposed approach.



## **Trust Performance Report Month 11**

Trust Board 26<sup>th</sup> April 2020






### RTT



# **Elective Activity - RTT 2019/2020 Trajectory**

Please note the SPC graph has been calculated using 24 point, however only 14 points are illustrated



**Feb 20** – month saw continued pressure on elective activity due to use of DSUs

### Key actions for March 2020:


- Focus on Cancer and Urgent activity
- Dialogue with CCG re cancer and urgent referrals
- Capacity options reviewed in line with National Guidance

#### **Key risks:**

- Continued reduction in RTT f March 2020 given the current context.
- Increased 52 week waits risk of circa 12 for March 2020




## **RTT Waiting List Size Projection**





The total waiting list size for February is 19100, the proposed baseline for the Operational Plan 2020/21 is currently set at 19199. In January 2020 the number of 40+ week waiters stood at 131 - the number of 40+ week waits has risen to 160 for February 2020.

### RTT Best, Most and Worst case



End of Feb position was close to the update 'most likely' position. This is based on historical data - impact of Covid-19 not currently modelled.






# **Diagnostics**



## **Diagnostics Waiting Time**



Endoscopy remains close to 99% target

### **Key Actions:**

Additional CT, Ultrasound and MRI sessions Additional Cardiorespiratory sessions – gap is closing

### **Key Risks:**

Covid 19 impact has resulted in significant changes to capacity for March

|                           |  | Total WL | Total >6wks | Proc Perf | Total WL | Over 6wks | Performance |
|---------------------------|--|----------|-------------|-----------|----------|-----------|-------------|
|                           | Magnetic Resonance Imaging                   | 2489     | 230         | 90.8%     |          |           |             |
| Imaging                   | Computed Tomography                          | 1578     | 111         | 93.0%     | 7145     | 481       | 93.27%      |
|                           | Non-obstetric ultrasound                     | 3078     | 140         | 95.5%     |          |           |             |
|                           | Audiology - Audiology Assessments            | 349      | 5           | 98.6%     |          |           |             |
|                           | Cardiology - echocardiography                | 425      | 6           | 98.6%     |          |           |             |
| Physiological Measurement | Neurophysiology - peripheral neurophysiology | 38       | 7           | 81.6%     | 895      | 48        | 94.64%      |
|                           | Respiratory physiology - sleep studies       | 24       | 4           | 83.3%     |          |           |             |
|                           | Urodynamics - pressures & flows              | 59       | 26          | 55.9%     |          |           |             |
|                           | Colonoscopy                                  | 312      | 3           | 99.0%     |          |           |             |
| Endoscony                 | Flexi sigmoidoscopy                          | 153      | 0           | 100.0%    | 1000     | 16        | 98.40%      |
| Endoscopy                 | Cystoscopy                                   | 127      | 8           | 93.7%     | 1000     | 16        | 36.40%      |
|                           | Gastroscopy                                  | 408      | 5           | 98.8%     |          |           |             |
|                           | Total  | 9040     | 545         |           | 9040     | 545       | 93.97%      |






### Cancer



# Cancer 2 Week Wait Trajectory 2019/20



#### February 2020 predicted figures

| Cancer Waiting Times - 2 Week Wait      | Apr-19 | May-19 | Jun-19 | Jul-19 | Aug-19 | Sep-19 | Oct-19 | Nov-19 | Dec-19 | Jan-20 | Feb-20 | Mar-20 |
|---|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| Trajectory Number Seen < 2 Wks          | 1,923  | 2,216  | 2,075  | 2,177  | 2,143  | 2,009  | 2,342  | 2,290  | 2,016  | 2,112  | 2,203  | 2,287  |
| Trajectory Total Number Seen            | 2,095  | 2,388  | 2,238  | 2,322  | 2,288  | 2,154  | 2,487  | 2,435  | 2,161  | 2,257  | 2,348  | 2,432  |
| Trajectory Performance % (93% standard) | 91.8%  | 92.8%  | 92.7%  | 93.8%  | 93.7%  | 93.3%  | 94.2%  | 94.0%  | 93.3%  | 93.6%  | 93.8%  | 94.0%  |
| Actual Number Seen < 2 Wks              | 1905   | 1843   | 1914   | 2073   | 1980   | 2083   | 2336   | 2175   | 2132   | 2043   | 2169   |        |
| Actual Total Number Seen                | 2317   | 2296   | 2344   | 2535   | 2322   | 2248   | 2520   | 2403   | 2334   | 2180   | 2289   | _      |
| Actual Performance % (93% standard)     | 82.2%  | 80.3%  | 81.7%  | 81.8%  | 85.3%  | 92.7%  | 92.7%  | 90.5%  | 91.3%  | 93.7%  | 94.8%  |        |


### **Key Actions 2020**

- Continue to introduce telephone booking as preferential booking format for additional specialties.
- The use of the electronic triage function to further speed up the triage process for 2WW referrals

### **Key Risks**

- Delay in GMC registration for consultant radiologist, expected to be approved by March 2020.
- Capacity for all 2 week wait patients in target.
- Covid-19 will impact in March 20


# **Cancer Performance 31 Day Wait Summary**



#### February 2020 predicted figures

| Cancer Waiting Times - 31 Day First Treatment | Apr-19 | May-19 | Jun-19 | Jul-19 | Aug-19 | Sep-19 | Oct-19 | Nov-19 | Dec-19 | Jan-20 | Feb-20 | Mar-20 |
|---|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| Number Treated < 31 Days                      | 248    | 267    | 280    | 262    | 280    | 270    | 273    | 275    | 249    | 260    | 254    | 268    |
| Total Number Seen                             | 250    | 269    | 283    | 264    | 282    | 274    | 273    | 277    | 253    | 262    | 255    | 269    |
| Performance % (96% standard)                  | 99.2%  | 99.3%  | 98.9%  | 99.2%  | 99.3%  | 98.5%  | 100.0% | 99.3%  | 98.4%  | 99.2%  | 99.6%  | 99.6%  |
| Number Treated < 31 Days                      | 272    | 274    | 237    | 290    | 277    | 269    | 303    | 256    | 248    | 274    | 218    |        |
| Total Number Seen                             | 279    | 280    | 244    | 299    | 282    | 273    | 311    | 261    | 255    | 282    | 226    |        |
| Performance % (96% standard)                  | 97.5%  | 97.9%  | 97.1%  | 97.0%  | 98.2%  | 98.5%  | 97.4%  | 98.1%  | 97.3%  | 97.2%  | 96.5%  |        |

### **Cancer 62 Day GP Referral**



#### February 2020 predicted figures

| Cancer Waiting Times - 62 Day GP Referral   | Apr-19 | May-19 | Jun-19 | Jul-19 | Aug-19 | Sep-19 | Oct-19 | Nov-19 | Dec-19 | Jan-20 | Feb-20 | Mar-20 |
|---|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| Ongoing Forecast - Number Treated < 62 Days | 106    | 122    | 132    | 115    | 142    | 87     | 94     | 123    | 118    | 123    | 103    | 111    |
| Total Number Seen                           | 141    | 154    | 162    | 141    | 168    | 129    | 133    | 162    | 153    | 161    | 129    | 133    |
| Performance % (85% standard)                | 75.1%  | 79.2%  | 81.4%  | 81.5%  | 84.5%  | 67.7%  | 70.9%  | 76.2%  | 77.1%  | 76.4%  | 80.2%  | 83.5%  |
| Number Treated < 62 Days                    | 114.5  | 122    | 109.5  | 125.5  | 103    | 100    | 136    | 114    | 115    | 117    | 87     |        |
| Total Number Seen                           | 158    | 162.5  | 153    | 170    | 140.5  | 144    | 177.5  | 149    | 147    | 169    | 135    |        |
| Performance % (85% standard)                | 72.5%  | 75.1%  | 71.6%  | 73.8%  | 73.3%  | 69.4%  | 76.6%  | 76.5%  | 78.2%  | 69.2%  | 64.4%  |        |


### **Key Actions**

- Introduction of weekly Cancer Assurance and Performance meetings
- Macmillan project managers aligned to key specialties
- Capacity review
- NHSI supported improvement planning

### **Key Risks**


- Urology capacity due to workforce gaps.
- Anaesthetic capacity to support additional lists
- Impact of 2ww lung capacity on 62 day performance.

### **Cancer Performance By Tumour – January 2020**



#### 2 Week Wait:

There are currently significant delays for Oncology appointments for certain specialties (up to 3 weeks or more) as a result of capacity issues.





#### 62 Day:

Current prediction for February 2020 is at 80.2%. The reduction in performance is as a result of clearing the backlog of patients waiting over 62days.

Lung, Urology and Lower/Upper GI remain risk areas

# 104 day breaches





- 1 x Colorectal (105 days) Delays for multiple diagnostics
- 1 x Colorectal (118 days) Treatment delayed for medical reasons.
- 1 x Gynae (109 days) Treatment delayed for medical reasons
- 1 x Haematology (167 days) Clinical decision / patient choice.
- 1 x UGI (107 days) Complex diagnostic pathway
- $1\,\mathrm{x}$  UGI (115 days) Complex pathway / treatment delayed for medical reasons. Initial referral to colorectal.
- 1 x UGI (142 days) Delays following tertiary referral referral made to QE day 31


- 1 x Urology (115 days) Elective capacity inadequate / delay for diagnostics.
- 1 x Urology (151 days) Diagnosis delayed for medical.
- 1 x Urology (122 days) Late tertiary referral / delays following tertiary referral
- 1 x Urology (105 days) Diagnosis delayed for medical reasons
- 1 x Urology (113 days) Delay for diagnostics / elective capacity / patient choice.
- 1 x Urology (137 days) Delays for diagnostics.
- 1 x Urology (134 days) Patient choice to delay diagnostic



# **Urgent Care Update**



### **A&E Performance**



### The following recovery actions are included within the trajectory:


- Reduction in 4 4 1/2 hour breaches validation process
- Maintaining Minors performance
- · Utilisation of CDU
- · Paediatric patients streamed/triaged
- Involvement of specialties in timely assessment and transfer

- Improved ED systems and processes
- Adhering to Internal Professional Standards





### **A&E Breaches**


Together We Achieve



### **Minor 4 Hours Performance**










## **Ambulance arrivals and handover delays**

Please note the SPC graph has been calculated using 24 point, however only 14 points are illustrated

Feb-20 Actual Arrivals: 3,533

Feb-20 Trajectory: 4,442

Variance to Trajectory -909



Handover breaches by time band for Feb 2020:

Please note based on WMAS Figures

|        |            | Trajectory |         |
|--------|------------|------------|---------|
|        | 15-30 mins | 30-60 mins | >60mins |
| Feb-20 | 2,357      | 704        | 159     |

| Actual     |            |         |  |  |  |  |  |
|------------|------------|---------|--|--|--|--|--|
| 15-30 mins | 30-60 mins | >60mins |  |  |  |  |  |
| 1,391      | 785        | 236     |  |  |  |  |  |

| % Variance Trajectory vs Actual |                        |  |  |  |  |  |  |
|---------------------------------|------------------------|--|--|--|--|--|--|
| 15-30 mins                      | ins 30-60 mins >60mins |  |  |  |  |  |  |
| -40.98%                         |                        |  |  |  |  |  |  |

The volume of Ambulance demand has continued to remain below initial predictions in Feb, although peaks on certain times/days remain challenging. SATH continues to work with system wide handover group and West Midlands Ambulance Service to reduce overall handover delays and drive alternate pathways.

As part of recent Risk Summit actions, 7 vehicles per day are being transferred from SATH to UHNM and RWT (primarily 0800-1200)



# **Finance Report Month 11**



### Finance Overview Month 11 – In month

|  | Annual    |
|--|-----------|
|  | NHSI Plan |
|  | £000s     |
|  |           |
| Income   | 345,477   |
| Income for pass through costs (Excluded medicines and devices) | 33,382    |
| Pay  | (273,760) |
| Non-Pay & General Reserves                                     | (76,109)  |
| Non-pay pass through costs                                     | (33,382)  |
| Reserves   | 1,200     |
| Total expenditure  | (382,051) |
| EBITDA   | (3,192)   |
| Finance Costs  | (14,159)  |
| Surplus/(deficit) against Control Total pre Support            | (17,351)  |
| Provider Support   | 17,351    |
| Surplus/(deficit) against Control Total post PSF               | 0         |

| In Month |          |          |  |  |  |  |  |  |
|----------|----------|----------|--|--|--|--|--|--|
| Plan     | Actual   | Variance |  |  |  |  |  |  |
| £000s    | £000s    | £000s    |  |  |  |  |  |  |
|          |          |          |  |  |  |  |  |  |
| 28,253   | 29,105   | 852      |  |  |  |  |  |  |
| 2,731    | 3,151    | 420      |  |  |  |  |  |  |
| (23,248) | (24,515) | (1,267)  |  |  |  |  |  |  |
| (6,349)  | (9,297)  | (2,948)  |  |  |  |  |  |  |
| (2,731)  | (3,151)  | (420)    |  |  |  |  |  |  |
| 100      | 0        | (100)    |  |  |  |  |  |  |
| (32,228) | (36,963) | (4,735)  |  |  |  |  |  |  |
| (1,244)  | (4,707)  | (3,463)  |  |  |  |  |  |  |
| (1,135)  | (698)    | 437      |  |  |  |  |  |  |
| (2,379)  | (5,405)  | (3,026)  |  |  |  |  |  |  |
| 1,866    | 397      | (1,469)  |  |  |  |  |  |  |
| (513)    | (5,008)  | (4,495)  |  |  |  |  |  |  |

### **Key Message**

• In month the Trust has an adverse variance to plan, and therefore control total, of £4.5m. Key points of note include:

Income – £1.3m above planned levels in-month (excluding pass through and provider support)

• Pass through income is £0.4m above plan and offsets the additional expenditure in-month.

#### Pay - £1.3m above plan

- Pay expenditure in month 11 increased by £0.2m compared to month 10.
- Within the month 11 position non-delivery of CIP amounted to £0.1m, and agency usage is £0.7m above plan.

### Non Pay – £3.3m above plan

- CNST Repayment, £1.0m
- Diagnostic reporting and send away tests, £0.6m
- Non-delivery of CIP, £0.2m
- Pass through devices £0.4m
- Clinical supplies, £0.3m
- Estates Maintenance contracts, £0.2m
- Drugs, £0.2m
- Overseas Nursing Recruitment Fees, £0.2m
- Radiology legacy Equipment, £0.1m
- Purchase of care home beds £0.1m

Provider support has been adjusted in light of the Trust's current forecast outturn, and this creates a £1.5m in-month adverse variance.



### Finance Overview Month 11 – Year to Date

|  | Annual    |           | YTD       |          |
|--|-----------|-----------|-----------|----------|
|  | NHSI Plan | Plan      | Actual    | Variance |
|  | £000s     | £000s     | £000s     | £000s    |
|  |           |           |           |          |
| Income   | 345,477   | 316,853   | 329,194   | 12,341   |
| Income for pass through costs (Excluded medicines and devices) | 33,382    | 30,622    | 30,901    | 279      |
| Pay  | (273,760) | (251,718) | (260,234) | (8,516)  |
| Non-Pay & General Reserves                                     | (76,109)  | (71,029)  | (88,313)  | (17,284) |
| Non-pay pass through costs                                     | (33,382)  | (30,622)  | (30,901)  | (279)    |
| Reserves   | 1,200     | 1,100     | 1,200     | 100      |
| Total expenditure  | (382,051) | (352,269) | (378,248) | (25,979) |
| EBITDA   | (3,192)   | (4,794)   | (18,153)  | (13,359) |
| Finance Costs  | (14,159)  | (12,509)  | (11,771)  | 738      |
| Surplus/(deficit) against Control Total pre Support            | (17,351)  | (17,303)  | (29,924)  | (12,621) |
| Provider Support   | 17,351    | 15,488    | 8,770     | (6,718)  |
| Surplus/(deficit) against Control Total post PSF               | 0         | (1,815)   | (21,154)  | (19,339) |

#### Income & Expenditure Position Month 11, Year to Date

The Trust has a planned deficit, pre support funding, of £17.3m for the period April 2019 to February 2020. The actual deficit reported for the same period is £29.9m, being £12.6m adverse to plan.

### Income – £12.6m favourable variance, excluding provider support funding

- Non elective activity £2.4m (0.3%) above plan.
- A&E activity £0.9m (3.5%) above plan.
- Non Elective Other (Maternity) £1.7m
- Additional £0.3m for posts funded externally including Health Education England.
- Deferred Income and Education income release £0.4m
- Assumed Readmission income of £1.5m
- FIT Monies (Bowel Screening Equipment) of £0.6m

**Pay – £8.5m adverse variance**, as a result of an overspend on agency costs of £6.7m and non delivery of CIP of £2.4m.

### Non Pay (excl. pass through) – £17.3m adverse variance, main drivers:

 Additional senior appointments and organisational change payments £1.0m; CNST Repayment £1.0m; diagnostic reporting £2.4m; non delivery of CIP of £4.6m; additional costs of clinical waste, estate costs and facilities costs £2.3m; Clinical supplies £1.7m; RN recruitment £0.8m.

**Balance Sheet Review £1.2m.** Release of Balance Sheet items transacted in the Month 3 financial position.

**Provider support funding – £6.7m adverse variance.** The level of funding due to be received has been adjusted in light of the Trust's forecast outturn position.

**Forecast Outturn.** At Month 10 the Trust reported a forecast outturn deficit of £35.4m. A re-assessment of the forecast at Month 11, indicates that the most likely outturn remains a deficit of £35.4m, pre support funding.



### **Income Analysis by Activity Type**

|                                       | YTD      | YTD      | Variance | Variance % | YTD     | YTD     | Financial      |
|---------------------------------------|----------|----------|----------|------------|---------|---------|----------------|
|                                       | Budget   | Actual   |          |            | Budget  | Actual  | Variance Value |
|                                       | Activity | Activity | Activity |            | £000s   | £000s   | £000s          |
| Accident and Emergency (Attendances)  | 116,397  | 120,586  | 4,189    | 3.5%       | 17,688  | 18,597  | 909            |
| Outpatient Appts (Attendances)        | 394,778  | 390,726  | (4,052)  | (1.0%)     | 47,826  | 47,614  | (212)          |
| Elective Day Cases                    | 47,115   | 46,896   | (219)    | (0.5%)     | 29,808  | 29,030  | (778)          |
| Elective Inpatient (Spells)           | 4,597    | 4,960    | 363      | 7.3%       | 14,311  | 16,349  | 2,038          |
| Non Elective (Spells)                 | 54,807   | 54,956   | 149      | 0.3%       | 113,877 | 116,312 | 2,435          |
| Non Elective Other                    | 4,914    | 5,699    | 785      | 13.8%      | 10,262  | 11,916  | 1,654          |
| Others (Inc Reserves)                 |          |          |          |            | 113,703 | 120,278 | 6,574          |
| Total                                 | 622,606  | 623,823  | 1,217    | 0.2%       | 347,475 | 360,095 | 12,620         |
| Provider Sustainability Funding (PSF) |          |          |          |            | 15,488  | 8,770   | (6,718)        |
| Total after PSF                       | 622,606  | 623,823  | 1,217    | 0.2%       | 362,963 | 368,865 | 5,902          |

### **Key Messages**

- Income over performance of £12.6m year to date, excluding support. Non elective activity above plan by 0.3%, and circa 9% higher than activity levels in 18/19
- The Trust has now agreed a full-year settlement with its two main commissioners.

### Other Points of note:

- Accident and Emergency attendances are above planned levels by 3.5%, creating a positive variance to plan of £0.9m.
- Outpatient attendances are under planned levels by 1%
- Elective Inpatient spells are above planned levels by 363 spells, with a positive financial variance of £2m
- Non Elective activity is 149 spells, 0.3%, higher than the planned levels; this includes the clinical decisions unit (CDU) at the PRH site
- Blended tariff adjustment the contract adjustment to income values for non elective and Accident & Emergency activity amounted to £6.1m
- Other income includes readmissions income of £1.5m and FIT (Bowel Screening Equipment) monies of £0.6m

## **CIP Delivery**

|                        | Y             | ear to Date     | •                 | Forecast Outturn |                 |                   |  |
|------------------------|---------------|-----------------|-------------------|------------------|-----------------|-------------------|--|
| CIP Programme          | Plan<br>£000s | Actual<br>£000s | Variance<br>£000s | Plan<br>£000s    | Actual<br>£000s | Variance<br>£000s |  |
|                        |               |                 |                   |                  |                 |                   |  |
| Internal Core CIP Plan | 11,743        | 4,047           | (7,696)           | 12,901           | 4,870           | (8,031)           |  |
| Breakeven Schemes      | 5,751         | 5,349           | (402)             | 5,988            | 5,930           | (58)              |  |
| Total                  | 17,494        | 9,396           | (8,098)           | 18,889           | 10,800          | (8,089)           |  |
|                        |               |                 |                   |                  |                 |                   |  |


#### The Trust has delivered £9.40M CIP as at Month 11. This is made up of:

- Core CIPs have delivered £4.05m year to date against the NHSI submitted plan of £11.74m (34%). In month delivery of £0.43m.
- This is made up of £2.18m Recurrent and £1.87m Non-recurrent.
- Break-even schemes have delivered £5.35m YTD against a plan of £5.75m (93%). In month delivery of £0.36m.
- This is made up of £0.92m Recurrent and £4.43m Non-recurrent.
- As a result, the overall YTD CIP position is £9.40m delivered against an overall YTD Plan (Core + Breakeven) of £17.49m (53% of YTD delivery).

### The forecast outturn position includes the following:


- In delivery Core schemes are forecasting £4.87m of the £12.90m target (38%). A reduction of £0.36m from M10.
- This is made up of £2.44m Recurrent and £2.43m Non-recurrent.
- In delivery Break-even schemes are forecasting £5.93m of the £5.99m target (99%). An increase of £0.05m from M10.
- This is made up of £1.01m Recurrent and £4.91m Non-recurrent.
- As a result, the overall (Core + breakeven) forecast of in-delivery schemes is £10.80m of its £18.89m target (57%). A reduction of £0.14m from M10.

## Pay 2019/20



- At the end of February the pay budget is overspent by £8.5m, as a result of an overspend on agency costs (£6.7m), and non delivery of CIP (£2.4m).
- The overall run rate for February is £0.21m higher than January, within which Substantive staff costs have increased by £0.11m.
- The Trust continues to spend, on average, £1m per month more on agency than recorded in the previous year.
- The operationalisation of the ED nursing business case continues to be a financial concern with an increasing reliance on agency, which forms part of the Trust's increased spend compared to the previous year.
- Pay costs include the impact of an increase to bank rates for RNs (in ED and the existing enhanced areas) and HCAs from December onwards.
- The Trust, alongside Deloitte, have weekly panels to review the key staff groups using agency, with the aim of reducing this usage.

# **Agency Expenditure 2019/20**



| Annual         |                        |                           |                     | YTD                             |                                       |   |                     | In Month                        |   |
|----------------|------------------------|---------------------------|---------------------|---------------------------------|---------------------------------------|---|---------------------|---------------------------------|---|
| Agency Ceiling | NHSI<br>Agency<br>Plan | Agency<br>Ceiling<br>Plan | Agency<br>NHSI Plan | Agency<br>Expenditure<br>Actual | Variance Under/ (Over) Agency Ceiling | Variance<br>Under/<br>(Over)<br>Agency<br>NHSI Plan | Agency<br>NHSI Plan | Agency<br>Expenditure<br>Actual | Variance Under/ (Over) Agency NHSI Plan |
| £000s          | £000s                  | £000s                     | £000s               | £000s                           | £000s                                 | £000s   | £000s               | £000s                           | £000s                                   |
| 14,232         | 19,153                 | 13,046                    | 17,521              | 24,206                          | (11,160)                              | (6,685)   | 1,619               | 2,269                           | (650)                                   |

- Agency expenditure has exceeded budget by £0.7 m in month, £6.7m year to date, associated with unavailability and capacity issues.
- Expenditure in February is £0.8m more in the month than the average for 2018/19.
- The annual plan for agency is £19.1m, with an nationally set agency ceiling of £14.2m.

### **Non Pay**



- Month 11 non pay spend, excluding drugs and devices, was £9.3m in month and £88.3m for the year to date.
- Excluding pass through drugs and devices, in month non pay was overspent by £3.3m, and by £17.6m for the year to date. See Financial Overview for further details.
- The Month 11 position includes the repayment of prior year CNST rebate.

### **Forecast Outturn**

|  | In-month               |                         |                       |                         | Year to Date             |          | Forecast Outturn        |                          |                        |
|--|------------------------|-------------------------|-----------------------|-------------------------|--------------------------|----------|-------------------------|--------------------------|------------------------|
|  | Plan                   | Actual                  | Variance              | Plan                    | Actual                   | Variance | Plan                    | Actual                   | Variance               |
|  | £000s                  | £000s                   | £000s                 | £000s                   | £000s                    | £000s    | £000s                   | £000s                    | £000s                  |
| Income inc. pass through                                     | 30,984                 | 32,256                  | 1,272                 | 347,475                 | 360,095                  | 12,620   | 381,059                 | 392,791                  | 11,732                 |
| Pay  | (23,148)               | (24,515)                | (1,367)               | (250,618)               | (259,034)                | (8,416)  | (273,760)               | (283,946)                | (10,186)               |
| Non-Pay inc. pass through                                    | (9,080)                | (12,448)                | (3,368)               | (101,651)               | (119,214)                | (17,563) | (110,491)               | (130,962)                | (20,471)               |
| Total Expendtiture   | (32,228)               | (36,963)                | (4,735)               | (352,269)               | (378,248)                | (25,979) | (384,251)               | (414,908)                | (30,657)               |
| EBITDA Financing Costs                                       | <b>(1,244)</b> (1,135) | <b>(4,707)</b><br>(698) | <b>(3,463)</b><br>437 | <b>(4,794)</b> (12,509) | <b>(18,153)</b> (11,771) |          | <b>(3,192)</b> (14,159) | <b>(22,117)</b> (13,266) | <b>(18,925)</b><br>893 |
| Total pre support funding                                    | (2,379)                | (5,405)                 | (3,026)               | (17,303)                | (29,924)                 | (12,621) | (17,351)                | (35,383)                 | (18,032)               |
| Provider Support   | 1,866                  | 397                     | (1,469)               | 15,488                  | 8,770                    | (6,718)  | 17,351                  | 9,166                    | (8,185)                |
| Surplus/(deficit) against Control Total post support funding | (513)                  | (5,008)                 | (4,495)               | (1,815)                 | (21,154)                 | (19,339) | 0                       | (26,217)                 | (26,217)               |

- The forecast outturn at month 10 was a £35.4m deficit (pre support funding). A review of the month 11 information has not altered the most likely outturn of £35.4m deficit.
- The forecast income position includes the end of year settlement reached with the Trust's two main commissioners.
- CIP delivery within the forecast outturn is £4.87m against internal core schemes, and £5.93m against break-even schemes.
- There are a number of risks that continue to be monitored which include CIP delivery, Linen & laundry outsourcing and Pathology send away tests. The scale of these risks could be between £0.3m and £0.5m.



# **Appendices**



## **Normalised Income and Expenditure**

### **Underlying I&E Position**

|   | Month 1  | Month 2  | Month 3  | Month 4  | Month 5  | Month 6  | Month 7  | Month 8  | Month 9I | Month 10 | Month 11 | Total     |
|---|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|-----------|
|   | £000s     |
| Income (excluding PSF & Passthrough)                | 29,238   | 28,800   | 31,057   | 30,014   | 30,312   | 32,764   | 30,311   | 29,014   | 27,802   | 30,776   | 29,105   | 329,192   |
| Passthrough Income (excluded medicines and devices) | 2,363    | 2,829    | 2,735    | 3,028    | 2,646    | 2,658    | 3,080    | 2,809    | 2,568    | 3,034    | 3,151    | 30,901    |
| Income finalisation phasing                         | (566)    | 926      | 105      | 640      | (1,009)  | 565      | (36)     | 161      | 795      | (500)    | (1,081)  | 0         |
| Pay   | (23,408) | (23,029) | (22,980) | (23,206) | (23,057) | (23,624) | (24,002) | (23,780) | (24,330) | (24,303) | (24,515) | (260,234) |
| Non-Pay (exc Passthrough)                           | (7,268)  | (7,251)  | (7,945)  | (8,382)  | (8,108)  | (7,176)  | (8,254)  | (8,128)  | (8,549)  | (7,955)  | (9,297)  | (88,313)  |
| Passthrough costs                                   | (2,363)  | (2,829)  | (2,735)  | (3,028)  | (2,646)  | (2,658)  | (3,080)  | (2,809)  | (2,568)  | (3,034)  | (3,151)  | (30,901)  |
| Balance Sheet Write off                             |          |          | 1,200    |          |          |          |          |          |          |          |          | 1,200     |
| EBITDA  | (2,004)  | (554)    | 1,437    | (934)    | (1,862)  | 2,529    | (1,981)  | (2,734)  | (4,282)  | (1,982)  | (5,788)  | (18,154)  |
| Finance Costs                                       | (1,073)  | (1,140)  | (1,104)  | (1,109)  | (1,118)  | (1,093)  | (1,104)  | (1,106)  | (1,106)  | (1,106)  | (698)    | (11,757)  |
| Actual Deficit exc PSF                              | (3,077)  | (1,694)  | 333      | (2,043)  | (2,980)  | 1,436    | (3,085)  | (3,840)  | (5,388)  | (3,088)  | (6,486)  | (29,911)  |
| less Non Recurrent                                  |          |          |          |          |          |          |          |          |          |          |          | 0         |
| Phased Income Adjustment                            |          |          | (1,600)  |          |          | (1,300)  | 500      | 500      | 1,900    |          |          | 0         |
| Release of Deferred Income                          |          |          |          |          |          | (125)    |          |          |          |          |          | (125)     |
| Release of HEE Deferred Income                      |          |          |          |          |          | (290)    |          |          |          |          |          | (290)     |
| Readmission income                                  |          |          |          |          |          | (1,480)  |          |          |          |          |          | (1,480)   |
| Maternity Incentivisation Scheme                    |          |          |          |          |          | (512)    |          |          | 512      |          |          | 0         |
| Cost of Organisational change                       |          |          |          |          |          |          | 150      |          |          |          |          | 150       |
| Balance Sheet accrual release                       |          |          | (1,200)  |          |          |          |          |          |          |          |          | (1,200)   |
| Underlying Deficit                                  | (3,077)  | (1,694)  | (2,467)  | (2,043)  | (2,980)  | (2,271)  | (2,435)  | (3,340)  | (2,976)  | (3,088)  | (6,486)  | (32,856)  |
| Planned Deficit                                     | (2,770)  | (840)    | (1,294)  | (836)    | (517)    | (2,437)  | (132)    | (768)    | (4,549)  | (4,549)  | (2,379)  | (21,071)  |
| Variance  | (307)    | (854)    | (1,173)  | (1,207)  | (2,463)  | 166      | (2,303)  | (2,572)  | 1,573    | 1,461    | (4,107)  | (11,785)  |



- The average underlying deficit in each of the first eleven months in circa £2.9m, a cumulative position of £32.9m, £11.8m above planned levels.
  - Income levels for individual months have been adjusted to reflect the actual income relating to the month, once all activity has been coded.

## **Capital Programme**

| 2019/20 Capital Programme Update as at Month 11 (February 2020)              |         |         |                  |                              |                      |                     |          |                  |
|--|---------|---------|------------------|------------------------------|----------------------|---------------------|----------|------------------|
|  | 2019/20 | 2010/20 | Franco di di con | Total                        | Expenditure          | Cahamanat           |          | Variance         |
|  | Capital |         | committed -      | expenditure/<br>committed to | committed -<br>to be | Scheme yet<br>to be | Forecast | under/<br>(over) |
| Scheme   | Budget  | date    | ordered          | date                         | ordered              | identified          | Outturn  | spend            |
|  | £000's  | £000's  | £000's           | £000's                       | £000's               | £000's              | £000's   | £000's           |
| Outstanding Commitments from 2018/19   | 46      | -3      | 9                | 6                            | 5                    | 0                   | 11       | 35               |
| PC In House costs of delivery of schemes                                     | 820     | 727     | 86               | 813                          | 0                    | 0                   | 813      | 7                |
| PC RSH MLU/PAU - P2 FCHS   | 0       | 0       | 0                | 0                            | 0                    | 0                   | 0        | 0                |
| PC Fire safety Programme   | 61      | 14      | 51               | 65                           | 0                    | 0                   | 65       | -4               |
| PC Subway Duct - RSH (further phases following on from 2017/18 agreement)    | 267     | 158     | 109              | 267                          | 0                    | 0                   | 267      | 0                |
| PC Ophthalmology move into Copthorne Building - Phase 3 (additional asbestos | 0       | 0       | 0                | 0                            | 0                    | 0                   | 0        | 0                |
| PC IT Storage Solution (further phases following on from 2018/19 investment) | 500     | 467     | 0                | 467                          | 0                    | 0                   | 467      | 33               |
| PC Replacement of Autoclaves in Path Lab (agreed at CPG)                     | 0       | 0       | 0                | 0                            | 0                    | 0                   | 0        | 0                |
| PC RSH Catering Service (agreed at CPG/PC)                                   | 98      | 34      | 61               | 95                           | 0                    | 0                   | 95       | 3                |
| PC Eye Injection Automation System (agreed at CPG)                           | 80      | 19      | 28               | 48                           | 32                   | 0                   | 80       | 0                |
| Total Delegated Contingency Funds  | 1,194   | 815     | 272              | 1,087                        | 23                   | 0                   | 1,110    | 84               |
| Corporate Contingency (In Year Allocations)                                  | 1,026   | 366     | 652              | 1,018                        | 3                    | 0                   | 1,021    | 5                |
| Capitalisation of Expenditure  | 1,400   | 1,198   | 155              | 1,352                        | 48                   | 0                   | 1,400    | 0                |
| Additional Capitalisation of Expenditure - FIT funding                       | 619     | 619     | 0                | 619                          | 0                    | 0                   | 619      | 0                |
| AS Endoscopy Suite Reconfiguration   | 1,300   | 0       | 0                | 0                            | 1,300                | 0                   | 1,300    | 0                |
| RF Fire Safety Copthorne Building (original balance)                         | 278     | 230     | 13               | 243                          | 35                   | 0                   | 278      | 0                |
| Uncommitted Fund Balance   | 752     | 0       | 0                | 0                            | 0                    | 0                   | 0        | 752              |
| UF High Value Radiology Equipment (inc PRH CT Scanner)                       | 400     | 377     | 0                | 377                          | 0                    | 0                   | 377      | 23               |
| UF Sustainable Services  | 400     | 384     | 29               | 413                          | 0                    | 0                   | 413      | -13              |
| UF Actions from CQC visit  | 97      | 7       | 22               | 29                           | 67                   | 0                   | 97       | 0                |
| Reallocated  | -771    | 0       | 0                | 0                            | 0                    | 0                   | 0        | -771             |
| IGDA - A&E System - System C   | 1,265   | 338     | 812              | 1,150                        | 107                  | 0                   | 1,257    | 8                |
| Rephased Capital Programme   | 22      | 0       | 0                | 0                            | 0                    | 0                   | 0        | 22               |
| RCP Windows 10 Rollout   | 374     | 35      | 352              | 386                          | 0                    | 0                   | 386      | -12              |
| RCP Additional MES funding   | 350     | 97      | 262              | 359                          | 0                    | 0                   | 359      | -9               |
| RCP Sustainable Services Project   | 774     | 637     | 137              | 774                          | 0                    | 0                   | 774      | 0                |
| RCP - Backlog Maintenance 19.20  | 405     | 0       | 8                | 8                            | 397                  | 0                   | 405      | 0                |
| RCP - Scoping  | 100     | 0       | 5                | 5                            | 95                   | 0                   | 100      | 0                |
| RCP - IT b/f 20.21   | 134     | 0       | 300              | 300                          | 0                    | 0                   | 300      | -166             |
| Total Internally Generated Capital Schemes                                   | 11,991  | 6,520   | 3,364            | 9,883                        | 2,112                | 0                   | 11,995   | -4               |
| NIY - Fire Safety Copthorne Building   | 1,622   | 499     | 962              | 1,461                        | 675                  | 0                   | 2,136    | -514             |
| NIY - Fire Safety Copthorne Building - Trust Contribution                    | 344     | 0       | 0                | 0                            | 0                    | 0                   | 0        | 344              |
| NIY - Additional Capacity - RSH/PRH  | 1,500   | 371     | 84               | 455                          | 0                    | 0                   | 455      | 1,045            |
| NIY - PRH Modular Build/Refurbishment of Wrekin MLU                          | 4,000   | 3,784   | 343              | 4,127                        | 23                   | 0                   | 4,149    | -149             |
| NIY-LED Lighting   | 427     | 600     | 0                | 600                          | 0                    |                     | 600      | -173             |
| NIY - Diagnostic Endoscopy   | 100     | 0       | 103              | 103                          | 0                    |                     | 103      | -3               |
| NIY - Data Warehouse   | 282     | 157     | 124              | 281                          | 0                    | 0                   | 281      | 1                |
| NIY - Digital Aspirants  | 3,000   | 0       |                  | 2,785                        | 215                  | 0                   | 3,000    | 0                |
| NIY-Pharmacy software Proud To Care  | 10      | 0       |                  | 4                            | 6                    | 0                   | 10       | 0                |
| NIY Reallocated  | -552    | 0       |                  | 0                            | 0                    | 0                   | 0        | -552             |
| Total Capital Programme Make It Happen                                       | 22,724  | 11,931  | 7,769            | 19,700                       | 3,029                | 0                   | 22,729   | -552             |
| %Total Capital Programme   | ,,      | 52.50%  | 34.19%           | 86.69%                       | 13.33%               | -0.03%              |          |                  |
| We Value Respect   | •       |         |                  |                              |                      |                     |          | 1                |

|   | Total C | RL      |
|---|---------|---------|
|   | £m      | %       |
| Expensed                                | 11.931  | 52.50%  |
| Ordered not<br>yet Expensed             | 7.769   | 34.19%  |
| Committed – not yet ordered or expensed | 3.029   | 13.33%  |
| To be identified/<br>overcommitted      | -0.006  | -0.03%  |
|   | 22.724  | 100.00% |

#### **Key Messages**

The CRL has increased by £1.9m from last month due to:

- removal of the external funding for Hospital Transformation Programme of £1.1m;
- increased by £3.0m in respect of funding for Digital Aspirants;
- increased by £0.01m for Pharmacy software allocation.


As reported last month, £0.64m was available for reallocation. As per delegated authority from Sustainability Committee and further to presentations to last month's CPG, this was allocated to Estates £0.41m for Urgent Estates Backlog Maintenance Issues and £0.10m for Scoping Works for Capacity Site Development.

The remaining £0.13m was allocated to IT Department to facilitate bringing forward the roll-out of Windows 10.

The Trust has been successful in its bid for Digital Aspirants funding and has received confirmation of an award of £3.0m this financial year.


### Cash

| The Shrewsbury and Telford Hospital NHS Trust     | Actual     |                |
|---|------------|----------------|
| Cashflow - 2019/20 as at M11                      | YTD        | Forecast Total |
| Casimow - 2010/20 as at in 11                     | £000's     |                |
| Balance B/fwd                                     | 1,649      | 1,649          |
| I&E CASHFLOW                                      |            |                |
| Income I&E (inc Donated & PSF)                    | 369,263    | 402,020        |
| Pay I&E   | (260, 566) | (286,068)      |
| Non Pay I&E                                       | (109,021)  | (125,061)      |
| Finance Costs I&E                                 | (1,926)    | (2,710)        |
| Capital Expenditure (inc Donated) re Depreciation | (3, 336)   | (11,618)       |
| Total I&E Cashflow (inc donated IGC)              | (5, 587)   | (23,437)       |
| EXTERNAL FUNDING                                  |            |                |
| Loan  | 5,203      | 18,573         |
| Expenditure - externally funded capital schemes   | (6,068)    | (8,096)        |
| Income - externally funded capital schemes        | 6,047      | 8,096          |
| Total External Funding Cashflow                   | 5,182      | 18,573         |
| Total Dalaman Charle Champion                     | E 070      | 4.045          |
| Total Balance Sheet Changes                       | 5,876      |                |
| Total Cashflow                                    | 5,471      | 51             |
| Balance C/fwd                                     | 7,120      | 1,700          |



- The Trust's current forecast outturn means that it will not be eligible for conditional funding for Q3 and Q4 (shortfall of £8.185m).
- The above cash flow is based on the revised forecast outturn. The Trust has a cash benefit in 2019/20 in respect of PSF funding relating to 2018/19 (£4.568m) and after taking account of movements in working balances, it is projected that the Trust will require external cash support of £18.573m to meet the year end cash requirement of £1.700m.
- The Trust has received cash support in lieu of conditional funding of £5.203m, which will be converted to I&E deficit support. Together with agreed I&E loan of £13.370m, the Trust will receive a total of £18.573m I&E cash support for 2019/20.
- The above cash flow assumes management of cash over the financial year in line with previous practice.

### Receivables



The outstanding receivables balances as at 29 February 2020 over £0.100m are:

|                                       | 1-30 Days | 31-60 Days | 61+ Days | Total |
|---------------------------------------|-----------|------------|----------|-------|
|                                       | £000s     | £000s      | £000s    | £000s |
| NHS England Commissioning             | 2,029     | -49        | 22       | 2,002 |
| Shropshire CCG                        | 472       | 106        | 19       | 597   |
| University Hospital of North Midlands | 202       | 0          | 62       | 264   |
| Shropshire Community Health Trust     | 144       | 45         | 39       | 228   |
| RJAH NHSFT                            | 86        | 50         | 85       | 221   |
| Royal Wolverhampton Hospital          | 56        | 57         | 60       | 173   |
| CP Plus                               | 124       | 0          | 0        | 124   |
| Lingen Davies                         | 119       | 0          | 0        | 119   |

- The 1-30 days balance with NHS England Commissioning includes £580k of invoices raised in advance for Month 12 contract income, to ensure these invoices are paid in March 2020. Other invoices raised to NHS England Commissioning in Month 11 relate to cancer drug fund (£510k), screening (£509k), funding for Welsh tariff (£275k) and midwifery review (£150k).
- There were no credit notes raised over £0.100m in February 2020.



## **Payables**


The Better Payment Practice code requires NHS bodies to aim to pay all valid invoices by the due date or within 30 days of receipt of valid invoice, whichever is later.


|   | Actual     | Actual     | Actual     | Actual     |
|---|------------|------------|------------|------------|
|   | 29/02/2020 | 29/02/2020 | 28/02/2019 | 28/02/2019 |
|   | YTD        | YTD        | YTD        | YTD        |
|   | Number     | £000s      | Number     | £000s      |
| Total invoices paid in the year           | 118,848    | 142,134    | 104,311    | 128,036    |
| Total invoices paid within target         | 31,552     | 50,555     | 34,466     | 51,666     |
| Percentage of invoices paid within target | 26.55%     | 35.57%     | 33.04%     | 40.35%     |

During February 2020 there were 515 invoices that were **not** paid within the Trust's 45 day payment target:

| Category | Number | £000s |
|----------|--------|-------|
| Agency   | 32     | 18    |
| NHS      | 15     | 68    |
| Other    | 169    | 611   |
| Pharmacy | 299    | 261   |
| Total    | 515    | 958   |

The Trust continues to manage its creditor position which includes processes which allow prioritisation of key suppliers who are paid within 30 days. The value of the monthly creditor suppression is shown below.





### **Appendix 2**

26 March 2020



## **Accountability and assurance**

### **Trust Board (TB)**

Trust Board holds the Executive Team to account for delivery of plan targets and objectives

Trust Board receives progress/performance updates



1

Trust Board delegates assurance activities (focused on the areas identified in the Board Assurance Framework)

Trust Board receives 'independent' assurance from ACs

Executive Team manages performance delivery by delegating responsibility through the line management structure and to a number of accountable teams / groups

### **Principles underpinning the Performance Management Framework**

- Ensuring all operational, financial and project targets, objectives and KPIs are fully understood and have been assigned to an appropriate business owner
- Sourcing high quality, accurate information in a timely fashion to measure performance against each objective and target (single version of the truth)
- Driving standardisation, consistency and alignment of performance dashboards and reports at all levels (including Trust Board) – 'exception-based' reporting wherever possible
- Maintaining standard templates and processes for concept briefs, business cases, project management etc.
- Constructively challenging performance delivery against agreed targets, confirming escalation criteria and recommending timely action(s) where appropriate

### **Assurance Committees (ACs)**

#### **Board Assurance committees**

Quality and Safety Committee
Audit and Risk Assurance Committee
Performance Committee
Sustainability Committee
Charitable Funds Committee
Workforce Committee

#### Additional time-limited committees

Maternity Taskforce Oversight Committee
Emergency Department Oversight Group
Recruitment and Retention Committee



## **Accountability triangle**





## **Example dashboards (normally A3)**



Develop performance dashboards (A3 'one pagers') for Board / Executive Team; Care groups / Corporate functions; Service lines

### Quality (select key metrics) e.g.

- SHMI
- Infections
- Harm free care
- Pressure Ulcers
- Falls
- Net promoter / Compliments and complaints
- Number of SIs

Year to date performance and end of year forecast vs targets (show as graphic/chart with RAG ratings)

### Financial (select key metrics) e.g.

- Financial I&E performance
- Capital spend
- CIPs
- · Cash and funding
- Regulatory rating

Year to date performance and end of year forecast vs targets (show as graphic/chart with RAG ratings)

### Operational (select key metrics) e.g.

- 18 weeks
- Cancer 62 day
- Diagnostics
- Emergency access (4 hour)
- Other

Year to date performance and end of year forecast vs targets (show as graphic/chart with RAG ratings)

### **Key plan milestones**

- Delivered in month
- On track for delivery next month
- Future milestones at risk and actions in place to address

### Overall progress assessment Year to date performance and end of year forecast vs targets (show as graphic/chart with RAG ratings)

### Workforce (select key metrics) e.g.

- FTEs employed
- Temporary / agency FTEs
- Staff turnover
- PDPs
- Absence (incl. long term)

Year to date performance and end of year forecast vs targets (show as graphic/chart with RAG ratings)

### **Summary and key risks**

e.g. Overall performance is progressing well against plan targets, further specific action is being taken to address:

- Implementing emergency access action plan
- Etc.

### Key risks include:

- Uncertainty about impact of 2019/20 tariff and commissioner allocations
- Etc.

